<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39386943</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>10</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>11</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2296-2565</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Frontiers in public health</Title><ISOAbbreviation>Front Public Health</ISOAbbreviation></Journal><ArticleTitle>Clinical characteristics and risk factors associated with diverse manifestations of COVID-19 in patients aged 85 years and older.</ArticleTitle><Pagination><StartPage>1407146</StartPage><MedlinePgn>1407146</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1407146</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fpubh.2024.1407146</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">The goal of this study is to assess the clinical attributes exhibited by patients aged 85 years and older who present different manifestations of COVID-19, and to examine the factors influencing the classification of the disease severity.</AbstractText><AbstractText Label="METHOD" NlmCategory="UNASSIGNED">This retrospective study was conducted at a single center, encompassing an analysis of clinical data obtained from patients with COVID-19 admitted to a general geriatric hospital in Hangzhou, Zhejiang, China, during the period from December 20, 2022, to February 1, 2023. The study focused on 91 eligible patients whose disease severity was compared based on the imaging findings.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">A total of 91 patients aged 85 years and older, with a median age of 92, including 46 males, 10 exhibiting mild symptoms, 48 moderate cases, and 33 severe cases met the inclusion criteria. Notably, disease severity displayed a significant correlation with age (<i>p</i> &lt; 0.011). All patients presented with complicated chronic underlying conditions and a history of prolonged medication use. Rheumatic immune diseases (<i>p</i> = 0.040) and endocrine medications, primarily hypoglycemic agents (<i>p</i> = 0.034), exhibited statistical significance. Additionally, markers such as lactate dehydrogenase (LDH) (<i>p</i> = 0.030), interleukin 6 (IL-6) (<i>p</i> = 0.014), and D-dimer (<i>p</i> = 0.007) revealed significant associations with disease severity. Chest computed tomography scans predominantly revealed inflammatory features (<i>n</i> = 81, 89.0%). Notably, patients classified as having mild or moderate conditions exhibited eventual improvement, while 13 patients (39.4%) among the severe cases succumbed to the disease.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">The classification of disease among patients aged 85 years or older old is correlated with advanced age, concurrent rheumatic immune diseases, and prolonged administration of endocrine medications. Furthermore, patients with elevated levels of LDH, IL-6, and D-dimer demonstrated a higher propensity for developing severe diseases.</AbstractText><CopyrightInformation>Copyright © 2024 Xu, Yang, Xin and Shou.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Zao-Xian</ForeName><Initials>ZX</Initials><AffiliationInfo><Affiliation>Department of Cardiac Rehabilitation, Zhejiang Hospital, Hangzhou, Zhejiang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Yi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Cardiac Rehabilitation, Zhejiang Hospital, Hangzhou, Zhejiang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xin</LastName><ForeName>Shang-Ping</ForeName><Initials>SP</Initials><AffiliationInfo><Affiliation>Department of Cardiac Rehabilitation, Zhejiang Hospital, Hangzhou, Zhejiang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shou</LastName><ForeName>Xiao-Ling</ForeName><Initials>XL</Initials><AffiliationInfo><Affiliation>Department of Cardiac Rehabilitation, Zhejiang Hospital, Hangzhou, Zhejiang, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Public Health</MedlineTA><NlmUniqueID>101616579</NlmUniqueID><ISSNLinking>2296-2565</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="Y">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002681" MajorTopicYN="N" Type="Geographic">China</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">aged 85 years or older</Keyword><Keyword MajorTopicYN="N">clinical characteristics</Keyword><Keyword MajorTopicYN="N">disease severity</Keyword><Keyword MajorTopicYN="N">risk factors</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>10</Day><Hour>6</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>10</Day><Hour>6</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>10</Day><Hour>5</Hour><Minute>16</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39386943</ArticleId><ArticleId IdType="pmc">PMC11461220</ArticleId><ArticleId IdType="doi">10.3389/fpubh.2024.1407146</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization . WHO COVID-19 dashboard, date of resource creation (2023). Available at: https://data.who.int/dashboards/covid19/cases (accessed September 13, 2023)</Citation></Reference><Reference><Citation>General Office of National Health Commission of the People’s Republic of China . Diagnosis and treatment of the coronavirus disease 2019 (the 10th version). China Medicine (2023) 18:161–6. doi: 10.3760/j.issn.1673-4777.2023.02.001</Citation><ArticleIdList><ArticleId IdType="doi">10.3760/j.issn.1673-4777.2023.02.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. . Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. (2020) 395:507–13. doi: 10.1016/S0140-6736(20)30211-7, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30211-7</ArticleId><ArticleId IdType="pmc">PMC7135076</ArticleId><ArticleId IdType="pubmed">32007143</ArticleId></ArticleIdList></Reference><Reference><Citation>Sankar K, Modi N, Polyak A, Directo MP, Johnson LR, Kho N, et al. . Comparison of clinical characteristics and outcomes of critically ill adults with SARS-CoV-2 infection during Delta and omicron variant predominance periods: a single-hospital retrospective cohort study. BMJ Open Respir Res. (2023) 10:e001274. doi: 10.1136/bmjresp-2022-001274, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjresp-2022-001274</ArticleId><ArticleId IdType="pmc">PMC9943693</ArticleId><ArticleId IdType="pubmed">36805880</ArticleId></ArticleIdList></Reference><Reference><Citation>Greene SK, Levin-Rector A, Kyaw NTT, Luoma E, Amin H, McGibbon E, et al. . Comparative hospitalization risk for SARS-CoV-2 omicron and Delta variant infections, by variant predominance periods and patient-level sequencing results, new York City, august 2021-January 2022. Influenza Other Respir Viruses. (2023) 17:e13062. doi: 10.1111/irv.13062, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/irv.13062</ArticleId><ArticleId IdType="pmc">PMC9835408</ArticleId><ArticleId IdType="pubmed">36317297</ArticleId></ArticleIdList></Reference><Reference><Citation>Strasser ZH, Greifer N, Hadavand A, Murphy SN, Estiri H. Estimates of SARS-CoV-2 omicron BA.2 subvariant severity in New England. JAMA Netw Open. (2022) 5:e2238354. doi: 10.1001/jamanetworkopen.2022.38354</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.38354</ArticleId><ArticleId IdType="pmc">PMC9597387</ArticleId><ArticleId IdType="pubmed">36282501</ArticleId></ArticleIdList></Reference><Reference><Citation>Xing Y, Sun Y, Tang M, Huang W, Luo J, Ma Q. Variables associated with 30-day mortality in very elderly COVID-19 patients. Clin Interv Aging. (2023) 18:1155–62. doi: 10.2147/CIA.S417282, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/CIA.S417282</ArticleId><ArticleId IdType="pmc">PMC10386830</ArticleId><ArticleId IdType="pubmed">37522071</ArticleId></ArticleIdList></Reference><Reference><Citation>Farshbafnadi M, Kamali Zonouzi S, Sabahi M, Dolatshahi M, Aarabi MH. Aging &amp; COVID-19 susceptibility, disease severity, and clinical outcomes: the role of entangled risk factors. Exp Gerontol. (2021) 154:111507. doi: 10.1016/j.exger.2021.111507, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.exger.2021.111507</ArticleId><ArticleId IdType="pmc">PMC8329427</ArticleId><ArticleId IdType="pubmed">34352287</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Klein SL, Garibaldi BT, Li H, Wu C, Osevala NM, et al. . Aging in COVID-19: vulnerability, immunity and intervention. Ageing Res Rev. (2021) 65:101205. doi: 10.1016/j.arr.2020.101205, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arr.2020.101205</ArticleId><ArticleId IdType="pmc">PMC7604159</ArticleId><ArticleId IdType="pubmed">33137510</ArticleId></ArticleIdList></Reference><Reference><Citation>Tizazu AM, Mengist HM, Demeke G. Aging, inflammaging and immunosenescence as risk factors of severe COVID-19. Immun Ageing. (2022) 19:53. doi: 10.1186/s12979-022-00309-5, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12979-022-00309-5</ArticleId><ArticleId IdType="pmc">PMC9650172</ArticleId><ArticleId IdType="pubmed">36369012</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu C, Chen X, Cai Y, Xia J’, Zhou X, Xu S, et al. . Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. (2020) 180:934–43. doi: 10.1001/jamainternmed.2020.0994, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2020.0994</ArticleId><ArticleId IdType="pmc">PMC7070509</ArticleId><ArticleId IdType="pubmed">32167524</ArticleId></ArticleIdList></Reference><Reference><Citation>United Nations . Department of Economic and Social Affairs Population Division, Word population prospects. (2022). Available at: https://population.un.org/wpp/DateSources (accessed September 13, 2023)</Citation></Reference><Reference><Citation>Tindale LC, Salema D, Brooks-Wilson AR. 10-year follow-up of the super-seniors study: compression of morbidity and genetic factors. BMC Geriatr. (2019) 19:58. doi: 10.1186/s12877-019-1080-8, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12877-019-1080-8</ArticleId><ArticleId IdType="pmc">PMC6394013</ArticleId><ArticleId IdType="pubmed">30819100</ArticleId></ArticleIdList></Reference><Reference><Citation>Halaschek-Wiener J, Tindale LC, Collins JA, Leach JA, McManus B, Madden K, et al. . The super-seniors study: phenotypic characterization of a healthy 85+ population. PLoS One. (2018) 13:e0197578. doi: 10.1371/journal.pone.0197578</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0197578</ArticleId><ArticleId IdType="pmc">PMC5967696</ArticleId><ArticleId IdType="pubmed">29795606</ArticleId></ArticleIdList></Reference><Reference><Citation>Murakami N, Hayden R, Hills T, al-Samkari H, Casey J, del Sorbo L, et al. . Therapeutic advances in COVID-19. Nat Rev Nephrol. (2023) 19:38–52. doi: 10.1038/s41581-022-00642-4, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41581-022-00642-4</ArticleId><ArticleId IdType="pmc">PMC9574806</ArticleId><ArticleId IdType="pubmed">36253508</ArticleId></ArticleIdList></Reference><Reference><Citation>RECOVERY Collaborative Group. Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, et al. . Dexamethasone in hospitalized patients with COVID-19. N Engl J Med. (2021) 384:693–704. doi: 10.1056/NEJMoa2021436, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2021436</ArticleId><ArticleId IdType="pmc">PMC7383595</ArticleId><ArticleId IdType="pubmed">32678530</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. . Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. (2020) 30:269–71. doi: 10.1038/s41422-020-0282-0, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41422-020-0282-0</ArticleId><ArticleId IdType="pmc">PMC7054408</ArticleId><ArticleId IdType="pubmed">32020029</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W, et al. . Oral Nirmatrelvir for high-risk, non-hospitalized adults with COVID-19. N Engl J Med. (2022) 386:1397–408. doi: 10.1056/NEJMoa2118542, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2118542</ArticleId><ArticleId IdType="pmc">PMC8908851</ArticleId><ArticleId IdType="pubmed">35172054</ArticleId></ArticleIdList></Reference><Reference><Citation>Jayk Bernal A, Gomes da Silva MM, Musungaie DB, Kovalchuk E, Gonzalez A, et al. . Molnupiravir for Oral treatment of COVID-19 in non-hospitalized patients. N Engl J Med. (2022) 386:509–20. doi: 10.1056/NEJMoa2116044, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2116044</ArticleId><ArticleId IdType="pmc">PMC8693688</ArticleId><ArticleId IdType="pubmed">34914868</ArticleId></ArticleIdList></Reference><Reference><Citation>Abadi B, Ilaghi M, Shahsavani Y, Faramarzpour M, Oghazian MB, Rahimi HR. Antibiotics with antiviral and anti-inflammatory potential against COVID-19: a review. Curr Rev Clin Exp Pharmacol. (2023) 18:51–63. doi: 10.2174/2772432817666220106162013, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/2772432817666220106162013</ArticleId><ArticleId IdType="pubmed">34994339</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi C, Qiu L, Zhuo J, Fang Y, Wang L, Xia J, et al. . Prevalence of inappropriate use of nirmatrelvir-ritonavir antiviral therapy in hospitalized patients: a multi-Centre retrospective study in China. Int J Antimicrob Agents. (2023) 62:106857. doi: 10.1016/j.ijantimicag.2023.106857, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijantimicag.2023.106857</ArticleId><ArticleId IdType="pmc">PMC10197429</ArticleId><ArticleId IdType="pubmed">37211263</ArticleId></ArticleIdList></Reference><Reference><Citation>Kartsonaki C, Baillie JK, Barrio NG, Baruch J, Beane A, Blumberg L, et al. . Characteristics and outcomes of an international cohort of 600000 hospitalized patients with COVID-19. Int J Epidemiol. (2023) 52:355–76. doi: 10.1093/ije/dyad012, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyad012</ArticleId><ArticleId IdType="pmc">PMC10114094</ArticleId><ArticleId IdType="pubmed">36850054</ArticleId></ArticleIdList></Reference><Reference><Citation>Siegel CH, Choi JM, D'Angelo D, Christos P, Lally L, Navarro-Millan I, et al. . Outcomes of COVID-19 and factors associated with its severity among hospitalized patients with and without systemic rheumatic disease during the first wave of the pandemic in new York City. J Clin Rheumatol. (2023) 29:7–15. doi: 10.1097/RHU.0000000000001891, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/RHU.0000000000001891</ArticleId><ArticleId IdType="pmc">PMC9803346</ArticleId><ArticleId IdType="pubmed">35905465</ArticleId></ArticleIdList></Reference><Reference><Citation>Bournia VK, Fragoulis GE, Mitrou P, Mathioudakis K, Tsolakidis A, Konstantonis G, et al. . Different COVID-19 outcomes among systemic rheumatic diseases: a nation-wide cohort study. Rheumatology. (2023) 62:1047–56. doi: 10.1093/rheumatology/keac422, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keac422</ArticleId><ArticleId IdType="pmc">PMC9384656</ArticleId><ArticleId IdType="pubmed">35920774</ArticleId></ArticleIdList></Reference><Reference><Citation>Taşdemir Mecit BB, Orhan S. Magnesemia in COVID-19 ICU patients: the relationship between serum magnesium level and mortality. magnesemia in COVID-19 ICU patients: the relationship between serum magnesium level and mortality. Magnes Res. (2022) 35:80–7. doi: 10.1684/mrh.2022.0504, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1684/mrh.2022.0504</ArticleId><ArticleId IdType="pubmed">36861811</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramos-Rincon JM, Buonaiuto V, Ricci M, Martín-Carmona J, Paredes-Ruíz D, Calderón-Moreno M, et al. . Clinical characteristics and risk factors for mortality in very old patients hospitalized with COVID-19 in Spain. J Gerontol A Biol Sci Med Sci. (2021) 76:e28–37. doi: 10.1093/gerona/glaa243, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/gerona/glaa243</ArticleId><ArticleId IdType="pmc">PMC7797762</ArticleId><ArticleId IdType="pubmed">33103720</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Valle DM, Kim-Schulze S, Huang HH, Beckmann ND, Nirenberg S, Wang B, et al. . An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat Med. (2020) 26:1636–43. doi: 10.1038/s41591-020-1051-9, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-1051-9</ArticleId><ArticleId IdType="pmc">PMC7869028</ArticleId><ArticleId IdType="pubmed">32839624</ArticleId></ArticleIdList></Reference><Reference><Citation>Short SAP, Gupta S, Brenner SK, Hayek SS, Srivastava A, Shaefi S, et al. . D-dimer and death in critically ill patients with coronavirus disease 2019. Crit Care Med. (2021) 49:e500–11. doi: 10.1097/CCM.0000000000004917, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0000000000004917</ArticleId><ArticleId IdType="pmc">PMC8275993</ArticleId><ArticleId IdType="pubmed">33591017</ArticleId></ArticleIdList></Reference><Reference><Citation>Dang JZ, Zhu GY, Yang YJ, Zheng F. Clinical characteristics of coronavirus disease 2019 in patients aged 80 years and older. J Integr Med. (2020) 18:395–400. doi: 10.1016/j.joim.2020.07.002, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.joim.2020.07.002</ArticleId><ArticleId IdType="pmc">PMC7347492</ArticleId><ArticleId IdType="pubmed">32690444</ArticleId></ArticleIdList></Reference><Reference><Citation>Bucci T, Galardo G, Gandini O, Vicario T, Paganelli C, Cerretti S, et al. . Fibrosis-4 (FIB-4) index and mortality in COVID-19 patients admitted to the emergency department. Intern Emerg Med. (2022) 17:1777–84. doi: 10.1007/s11739-022-02997-9, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11739-022-02997-9</ArticleId><ArticleId IdType="pmc">PMC9140323</ArticleId><ArticleId IdType="pubmed">35624344</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruggeri P, Esquinas A. Fibrosis-4 (FIB-4) index and mortality in COVID-19 patients admitted to the emergency department: a new interesting predictive index for patients with COVID-19 disease? Intern Emerg Med. (2022) 17:2451–2. doi: 10.1007/s11739-022-03067-w, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11739-022-03067-w</ArticleId><ArticleId IdType="pmc">PMC9374285</ArticleId><ArticleId IdType="pubmed">35962270</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>